---
title: "Advancing mRNA and CircRNA-based Vaccines and Therapeutics in CMC: From Process Development to Analytics"
description: In this webcast, learn how Innoforce is achieving scalable, high-quality production of RNA molecules through advanced process development and optimization.
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

#                                          ![New-ATE-Logo2019 (1)](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019%20(1).png?width=700&name=New-ATE-Logo2019%20(1).png)

# Advancing mRNA and CircRNA-based

# Vaccines and Therapeutics in CMC:

# From Process Development to Analytics

|  |
| --- |

## Presenter:

****![01-23-2025-Innoforce-Speaker-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/01-23-2025-Innoforce-Speaker-HS-Cropped.png?width=136&height=197&name=01-23-2025-Innoforce-Speaker-HS-Cropped.png)****

**Shanshan Wang, PhD**

*associate director,*

Innoforce Pharmaceuticals

 

Shanshan Wang, PhD earned her doctoral degree from Heidelberg University, Germany, and has over a decade of research experience in molecular biology and biochemistry, with six peer-reviewed publications to her name. She also brings more than six years of industrial expertise in biologics R&D and CMC.

Currently, Wang leads the RNA drug substance team at the RNA Center of Excellence at Zhejiang Innoforce Pharmaceutical. In this role, she oversees process development and technological innovation for plasmid and RNA platforms. Her responsibilities span from molecule design and optimization to process development, technology transfer, manufacturing support, and IND dossier preparation.

Wang has successfully managed numerous client and internal projects, including an end-to-end mRNA vaccine program that achieved FDA IND approval, demonstrating her expertise and leadership in advancing RNA-based therapeutics.

## About this event:

#### Date: January 23, 2025

#### Time: 11 am EST | 8 am PST | 5 pm CET

#### Duration: 30 minutes

| The therapeutic potential of mRNA-based therapies is rapidly being recognized across various fields, positioning the mRNA sector as a fast-emerging area of innovation. Beyond conventional mRNA, circular RNA (circRNA) and self-amplifying RNA (saRNA) are gaining significant attention as promising molecules for RNA-based vaccines and therapeutics. However, the development of circRNA and saRNA faces numerous CMC challenges, including impurity removal in circRNA production (e.g., precursor RNA and nicked RNA), process scalability, integrity analysis for both circRNA and saRNA, and effective encapsulation strategies. Innoforce’s RNA Center of Excellence is dedicated to achieving scalable, high-quality production of RNA molecules, including mRNA, circRNA, and saRNA, through advanced process development and optimization. Leveraging extensive platform development and project execution experience, they have successfully addressed critical process and analytical challenges to support the development of vaccines and therapeutics. Key Takeaways: - Learn about the background and process of mRNA, circRNA, and saRNA - Analyze encapsulation of mRNA, circRNA, and saRNA  - Gain insights into key challenges in circRNA and saRNA manufacturing, including case studies. |
| --- |

-  

-  

©2015 BioProcess International All Rights reserved